Showing results (111-120 of 135) with videos related to
Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2018
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapyY-P Chen, Y-Q Wang, J-W Lv, et al.The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.Cancer|November 21, 2015
Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapyJian Ji Pan, Wai Tong Ng, Jing Feng Zong, et al.Oncotarget|August 24, 2014
CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinomaOihana Murillo-Sauca, Man Ki Chung, June Ho Shin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2021
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu-Pei Chen, Nofisat Ismaila, Melvin L K Chua, et al.Journal of the National Cancer Institute|December 4, 2025
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experienceLuana G Sousa, James Edward Bates, Payal Anand, et al.Cancer|July 20, 2016
Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapyJian Ji Pan, Wai Tong Ng, Jing Feng Zong, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.Nature Biotechnology|June 3, 2026
Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumorsGuolan Lu, John W Hickey, Maximilian Haist, et al.International Journal of Radiation Oncology, Biology, Physics|October 13, 2022
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504Maura L Gillison, Robert L Ferris, Jonathan Harris, et al.Pageof 14